Reduce the risk of death by 32% Keytruda combination is fully approved to treat endometrial cancer

On July 22, 2021, Merck & Co.

Endometrial cancer is the most common type of cancer in the uterus

Keytruda/Lenvima combination therapy is an important cancer immune combination therapy jointly developed by Merck and Eisai

The approval of the combination therapy is based on the positive results obtained from a multi-center, open-label, randomized, and activity-controlled pivotal phase 3 clinical trial KEYNOTE-775

The test results showed that compared with standard chemotherapy, Keytruda/Lenvima showed a statistically significant improvement in overall survival (OS) and progression-free survival (PFS), reducing the risk of death by 32% (HR=0.

▲Efficacy data of Keytruda/Lenvima (picture source: reference [1])

The most common adverse reactions in the Keytruda/Lenvima group were hypothyroidism (67%), hypertension (67%), fatigue (58%), diarrhea (55%), musculoskeletal disease (53%), nausea (49%) ), decreased appetite (44%), vomiting (37%), stomatitis (35%), weight loss (34%), abdominal pain (34%), urinary tract infection (31%), proteinuria (29%), Constipation (27%), headache (26%), bleeding events (25%), palm and plantar swelling and pain (23%), dysphonia (22%), and skin rash (20%)

Note: The original text has been deleted

Reference materials:

[1] FDA Approves Keytruda® (pembrolizumab) Plus Lenvima® (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma.

[2] Once conditional, Merck's Keytruda, Eisai's Lenvima win full approval for endometrial cancer.

[3] Merck, Eisai notch full approval for Keytruda-TKI inhibitor combo in advanced endometrial cancer.